New Haven, Connecticut 06519


Purpose:

The purpose of this study is to investigate the effects of dietary exposure to artificial sweeteners on taste sensitivity, preference and brain response in adults. The investigators hypothesize that dietary exposure to artificial sweeteners (sucralose) will decrease sensitivity to taste, shift preference of sweet and savory taste to a higher dose, and reduce brain response in amygdala to sweet taste compared to sucrose.


Study summary:

We aim to identify neural factors that contribute to taste intensity perception in humans and to determine environmental mechanisms that contribute to variation in taste sensitivity. Significant controversy surrounds the possibility that consumption of artificial sweeteners (AFS) leads to weight gain. Given that the five FDA approved AFSs are found in thousands of foods (Yang 2010) this marks a clear and significant gap in knowledge. Our preliminary data demonstrate a 3-fold decrease in sweet taste sensitivity following consumption of a beverage sweetened with two packets of Splenda for just 10 days. These data provide strong evidence that repeated exposure to sucralose reduces perception of sweet taste intensity, most likely by down-regulation of the sweet taste receptor. Therefore, it is imperative that we gain a greater understanding of the physiological consequences of AFS, since alterations in sweet taste perception, metabolism and brain reward that occur in response to AFS exposure may promote weight gain.


Criteria:

Inclusion Criteria: - Healthy - Fluent in English - Right handed Exclusion Criteria: - History of oral nerve damage, - presence of known taste or smell disorder, - food allergies or sensitivities (for example nuts, lactose, artificial sweeteners), - history of CNS disease, - diabetes, - history of DSM-IV major psychiatric disorder, - including alcohol and substance abuse, - chronic use of medication that may affect taste, - conditions that may interfere with gustatory or olfactory perception (colds, seasonal allergies, - recent smoking history), - aberrant stimulus ratings, - contra-indication for fMRI, - uncomfortable swallowing in supine position, - discomfort or anxiety associated with insertion an intravenous catheter, - regular artificial sweetener use.


NCT ID:

NCT02335021


Primary Contact:

Principal Investigator
Dana M Small
The John B Pierce Laboratory, Yale University

Dana M Small
Phone: 2035629901 ext. 242
Email: dsmall@jbpierce.org


Backup Contact:

Email: egarcia@jbpierce.org
Elizabeth Garcia
Phone: 2035629901 ext. 210


Location Contact:

New Haven, Connecticut 06519
United States



There is no listed contact information for this specific location.

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: June 25, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.